Schizophrenia and co-occurring substance use disorder

American Journal of Psychiatry

Volumn 164, Issue 3, 2007, Pages 402-408

  Green, Alan I ^a,b   Drake, Robert E ^a   Brunette, Mary F ^a   Noordsy, Douglas L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; CANNABIS; CLOZAPINE; DESIPRAMINE; DISULFIRAM; HALOPERIDOL; IMIPRAMINE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; CANNABIS ADDICTION; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOMELESSNESS; HUMAN; LIVER TOXICITY; MALE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 34047128647     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.3.402     Document Type: Article

References (41)

1. Dixon L: Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35(suppl):S93-S100
2. Green AI, Tohen M, Hamer RM, Strakowski SM, Lieberman J, Glick I, Clark WS, Group HR: First-episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004; 66(2-3):125-135
3. Hambrecht M, Häfner H: Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40:1155-1163
4. Linszen D, Dingemans P, Lenior M: Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51:273-279
5. Mueser K, Drake R, Wallach M: Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23:717-734
6. Roth RM, Brunette MF, Green AI: Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 2005; 7:283-291
7. Fowles DC: Schizophrenia: diathesis-stress revisited. Annu Rev Psychol 1992; 43:303-336
8. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW: Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol Psychiatry 2005; 57:1117-1127
9. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH: Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57:594-608
10. Khantzian EJ: The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997; 4:231-244
11. Brunette M, Mueser KT, Drake RE, Xie H: Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185:13-20
12. Green AI, Zimmet SV, Strous RD, Schildkraut JJ: Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999; 6:287-296
13. Chambers AR, Krystal JH, Self DW: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001; 50:71-83
14. Gardner EL: Brain reward mechanisms, in Substance Abuse: A Comprehensive Textbook. Edited by Lowinson JH, Ruiz P, Millman RB, Langrod JG. Baltimore, Williams & Wilkins, 1997
15. Nissel M, Nomikos GG, Svensson TH: Nicotine dependence, midbrain dopamine systems, and psychiatric disorders. Pharmacol Toxicol 1995; 76:157-162
16. Rosenberg SD, Drake RE, Wolford GL, Mueser KT, Oxman TE, Vidaver RM, Carrieri KL, Luckoor R: Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. Am J Psychiatry 1998; 155:232-238
17. Drake RE, Mueser KT, McHugo GJ: Clinician Rating Scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS), in Outcomes Assessment in Clinical Practice. Edited by Sederer LI, Dickey B. Baltimore, Williams & Wilkins, 1996
18. Drake RE, Osher FC, Noordsy DL, Hurlbut SC, Teague GB, Beaudett MS: Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990; 16:57-67
19. McHugo GJ, Drake RE, Burton HL, Ackerson TH: A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 1995; 183:762-767
20. Drake RE, O'Neal EL, Wallach MA: A systematic review of psychosocial interventions for people with co-occurring substance use and severe mental disorders. J Subst Abuse Treat (in press)
21. Mueser KT, Noordsy D, Drake RE, Fox M: Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, Guilford, 2003
22. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006; 63:426-432
23. Drebing CE, Van Ormer EA, Krebs C, Rosenheck R, Rounsaville B, Herz L, Penk W: The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal 2005; 38:359-372
24. Brunette MF, Mueser KT, Drake RE: A review of residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev 2004; 23:471-481
25. Voruganti LNP, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185:463-465
26. McEvoy JP, Freudenreich O, Levin E, Rose JE: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995; 119:124-126
27. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C: Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51:531-538
28. Green AI, Noordsy DL, Brunette MF, O'Keefe C: Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat (in press)
29. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157:1835-1842
30. Drake RE, Xie H, McHugo GJ, Green AI: The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull 2000; 26:441-449
31. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32:637-643
32. Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, Kaune M: A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat 2004; 27:45-49
33. Green AI, Burgess ES, Zimmet SV, Dawson R, Strous RD: Alcohol and cannabis use in schizophrenia: effects of clozapine and risperidone. Schizophr Res 2003; 60:81-85
34. Petrakis I, Leslie D, Finney J, Rosenheck R: Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addictions 2006; 15:44-49
35. Smelson DA, Ziedonis D, Williams J, Losonczy MF, Steinberg ML, Kaune M: The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006; 26:9-12
36. Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, Caroff SN: Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005; 193:379-386
37. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005; 25:218-225
38. Siris SG, Mason SE, Bermanzohn PC, Shuwall MA, Aseniero MA: Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993; 29:127-133
39. Mueser KT, Noordsy DL, Fox L, Wolfe R: Disulfiram treatment for alcoholism in severe mental illness. Am J Addictions 2003; 12:242-252
40. Petrakis IL, Nich C, Ralevski E: Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006; 32:644-654
41. Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH; VA Naltrexone Study Collaboration Group: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2004; 172:291-297